ETF Holdings Breakdown of PRTA

News associated with PRTA

SG Americas Securities LLC Raises Stock Holdings in Prothena Corporation plc (NASDAQ:PRTA)

SG Americas Securities LLC increased its position in Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 92.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,559 shares of the biotechnology company’s stock after acquiring an additional 34,947 shares during the period. SG […] - 2025-06-19 07:30:54

Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Two Sigma Investments LP

Two Sigma Investments LP increased its stake in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 265.4% during the 4th quarter, Holdings Channel reports. The fund owned 38,394 shares of the biotechnology company’s stock after purchasing an additional 27,887 shares during the quarter. Two Sigma Investments LP’s holdings in Prothena were worth $532,000 as of […] - 2025-06-09 07:30:53

Hennion & Walsh Asset Management Inc. Buys 25,353 Shares of Prothena Co. plc (NASDAQ:PRTA)

Hennion & Walsh Asset Management Inc. lifted its holdings in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 48.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 77,637 shares of the biotechnology company’s stock after purchasing an additional 25,353 shares during the period. Hennion & Walsh Asset […] - 2025-06-08 08:53:06

Bank of America Corp DE Acquires 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA)

Bank of America Corp DE increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 45.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 119,007 shares of the biotechnology company’s stock after buying an additional 36,944 shares […] - 2025-06-05 08:14:52

Prothena (NASDAQ:PRTA) Earns “Underperform” Rating from Bank of America

Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating restated by stock analysts at Bank of America in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. A number of other analysts have also recently weighed in on PRTA. Cantor Fitzgerald cut shares of Prothena from an “overweight” rating to […] - 2025-05-30 08:06:52

Bank of America Reaffirms Underperform Rating for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating restated by research analysts at Bank of America in a note issued to investors on Wednesday, MarketBeat.com reports. A number of other equities analysts have also issued reports on PRTA. Cantor Fitzgerald lowered shares of Prothena from an “overweight” rating to a “neutral” rating […] - 2025-05-30 08:06:52

Prothena (NASDAQ:PRTA) Receives “Underperform” Rating from Bank of America

Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating reiterated by Bank of America in a research note issued to investors on Wednesday, Marketbeat Ratings reports. PRTA has been the topic of several other reports. Cantor Fitzgerald cut shares of Prothena from an “overweight” rating to a “neutral” rating in a report on […] - 2025-05-30 08:06:52

Prothena (NASDAQ:PRTA) Given Underperform Rating at Bank of America

Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating reiterated by stock analysts at Bank of America in a note issued to investors on Wednesday, MarketBeat.com reports. PRTA has been the topic of a number of other reports. Wall Street Zen upgraded Prothena from a “sell” rating to a “hold” rating in a […] - 2025-05-30 08:06:52

Prothena (NASDAQ:PRTA) Downgraded by Jefferies Financial Group to “Hold”

Prothena (NASDAQ:PRTA – Get Free Report) was downgraded by stock analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a report issued on Tuesday, Marketbeat Ratings reports. They presently have a $6.00 price target on the biotechnology company’s stock. Jefferies Financial Group’s target price indicates a potential upside of 30.43% […] - 2025-05-29 06:02:58

JMP Securities Lowers Prothena (NASDAQ:PRTA) Price Target to $29.00

Prothena (NASDAQ:PRTA – Get Free Report) had its target price cut by JMP Securities from $78.00 to $29.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. A number of other equities analysts have also commented on the company. Wall Street Zen raised Prothena […] - 2025-05-29 06:02:57

Prothena (NASDAQ:PRTA) Rating Lowered to Neutral at Cantor Fitzgerald

Prothena (NASDAQ:PRTA – Get Free Report) was downgraded by research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, MarketBeat reports. Several other equities research analysts have also recently issued reports on PRTA. Royal Bank of Canada lowered their price objective […] - 2025-05-29 06:02:53

HC Wainwright Cuts Prothena (NASDAQ:PRTA) Price Target to $14.00

Prothena (NASDAQ:PRTA – Get Free Report) had its price objective decreased by analysts at HC Wainwright from $30.00 to $14.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 204.35% from the company’s current […] - 2025-05-29 05:15:04

Piper Sandler Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price

Prothena (NASDAQ:PRTA – Free Report) had its target price decreased by Piper Sandler from $110.00 to $81.00 in a research report released on Tuesday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the biotechnology company’s stock. A number of other research firms have also commented on PRTA. Oppenheimer lowered Prothena from an “outperform” […] - 2025-05-28 07:46:49

Chardan Capital Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price

Prothena (NASDAQ:PRTA – Free Report) had its price objective lowered by Chardan Capital from $40.00 to $18.00 in a research note released on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. A number of other equities research analysts have also recently commented on the stock. Oppenheimer raised their […] - 2025-05-28 05:52:54

Traders Purchase High Volume of Put Options on Prothena (NASDAQ:PRTA)

Prothena Co. plc (NASDAQ:PRTA – Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock traders bought 8,185 put options on the company. This is an increase of approximately 1,210% compared to the average volume of 625 put options. Prothena Price Performance Shares of PRTA stock opened at $4.58 on Wednesday. […] - 2025-05-28 05:06:46

Balyasny Asset Management L.P. Makes New $527,000 Investment in Prothena Co. plc (NASDAQ:PRTA)

Balyasny Asset Management L.P. acquired a new position in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 38,021 shares of the biotechnology company’s stock, valued at approximately $527,000. Balyasny Asset Management L.P. […] - 2025-05-16 08:52:58

Raymond James Financial Inc. Takes Position in Prothena Co. plc (NASDAQ:PRTA)

Raymond James Financial Inc. purchased a new stake in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 13,111 shares of the biotechnology company’s stock, valued at approximately $182,000. Several other institutional investors and […] - 2025-05-13 07:18:47

Prothena (NASDAQ:PRTA) Price Target Lowered to $30.00 at HC Wainwright

Prothena (NASDAQ:PRTA – Free Report) had its price objective reduced by HC Wainwright from $48.00 to $30.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other brokerages have also weighed in on PRTA. Piper Sandler boosted their price objective on shares […] - 2025-05-12 05:44:45

JMP Securities Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price

Prothena (NASDAQ:PRTA – Free Report) had its target price reduced by JMP Securities from $80.00 to $78.00 in a report published on Friday morning,Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock. A number of other equities research analysts also recently issued reports on the stock. Cantor Fitzgerald reiterated an […] - 2025-05-12 05:44:45

Hsbc Holdings PLC Grows Holdings in Prothena Co. plc (NASDAQ:PRTA)

Hsbc Holdings PLC increased its stake in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 60.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 24,179 shares of the biotechnology company’s stock after purchasing an additional 9,101 shares during the period. Hsbc Holdings PLC’s holdings […] - 2025-05-09 08:41:02

Renaissance Technologies LLC Acquires 19,100 Shares of Prothena Co. plc (NASDAQ:PRTA)

Renaissance Technologies LLC increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 10.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,900 shares of the biotechnology company’s stock after purchasing an additional 19,100 shares during the period. […] - 2025-04-25 08:54:49

Corebridge Financial Inc. Trims Position in Prothena Co. plc (NASDAQ:PRTA)

Corebridge Financial Inc. trimmed its position in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 7.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,140 shares of the biotechnology company’s stock after selling 1,596 shares during the quarter. […] - 2025-04-11 08:40:59

Prothena Co. plc (NASDAQ:PRTA) Given Consensus Rating of “Moderate Buy” by Analysts

Prothena Co. plc (NASDAQ:PRTA – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among […] - 2025-04-11 07:32:50

KLP Kapitalforvaltning AS Acquires New Shares in Prothena Co. plc (NASDAQ:PRTA)

KLP Kapitalforvaltning AS acquired a new position in Prothena Co. plc (NASDAQ:PRTA – Free Report) in the fourth quarter, HoldingsChannel reports. The fund acquired 12,900 shares of the biotechnology company’s stock, valued at approximately $179,000. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PRTA. Orion Portfolio […] - 2025-04-09 07:28:47

Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers grew its stake in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 1.8% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 67,115 shares of the biotechnology company’s stock after buying an additional 1,175 shares during the period. Rhumbline Advisers’ holdings in Prothena were worth $930,000 as of its most recent filing […] - 2025-03-07 08:24:49

Prothena (NASDAQ:PRTA) Raised to “Hold” at StockNews.com

Prothena (NASDAQ:PRTA – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday. PRTA has been the topic of several other research reports. Oppenheimer lifted their price objective on Prothena from $58.00 to $62.00 and gave the stock an […] - 2025-02-26 06:52:50

Prothena Co. plc (NASDAQ:PRTA) Receives Average Rating of “Moderate Buy” from Analysts

Prothena Co. plc (NASDAQ:PRTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among […] - 2025-02-25 08:38:51

Prothena (NASDAQ:PRTA) Earns Buy Rating from HC Wainwright

Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $48.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 208.48% from the company’s previous […] - 2025-02-23 10:17:01

Prothena (NASDAQ:PRTA) & Annexon (NASDAQ:ANNX) Critical Comparison

Prothena (NASDAQ:PRTA – Get Free Report) and Annexon (NASDAQ:ANNX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Analyst Ratings This is a summary of current ratings […] - 2025-02-13 08:26:51

Head to Head Review: Prothena (NASDAQ:PRTA) and KALA BIO (NASDAQ:KALA)

Prothena (NASDAQ:PRTA – Get Free Report) and KALA BIO (NASDAQ:KALA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, analyst recommendations, profitability, institutional ownership and valuation. Earnings & Valuation This table compares Prothena and […] - 2025-02-12 06:27:08

PRTA institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	29,151	USD 180,153
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	65,278	USD 403,418
2025-06-19	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	66,254	USD 380,961
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	26,216	USD 162,015
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	26,216	USD 162,015
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	3,066	USD 18,948
Total =		216,181	USD 1,307,510

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer